摘要:
The present invention provides methods for diagnosing and treating cancer, and in particular methods for determining the susceptibility of subjects suspected of having breast cancer (or known to have breast cancer) to treatment with topoisomerase II inhibitors. The present invention also provides in situ hybridization probes for specifically detecting topoIIα gene sequences.
摘要:
The embodiments of the invention are multiple antibody immunoassay systems, and preferably immunohistochemical staining systems. In these systems the detection antibody system that detects the association of a targeting antibody (that binds to the target moiety to be detected) may also cross-react with endogenous immunoglobulins in the specimen in which the target moiety is to be detected, yielding an unreliable assay with high background levels. This problem has been overcome by a process that includes cross-linking a monovalent antibody to the endogenous antigenic determinants prior to exposure to the targeting antibody and detecting antibody system. The embodiments of the invention also include kits for use in these multiple antibody immunoassay and histochemical staining systems.
摘要:
The present invention relates to chromogenic (calorimetric) in situ hybridization (CISH) and nucleic acid probes useful for in situ hybridization. Specifically, the present invention provides methods, kits, and compositions for performing bright field cancer diagnostics employing chromogenic in situ hybridization (e.g. to detect gene amplifications, gene translocations, and chromosome polysomy). In preferred embodiments, the present invention provides CISH methods, kits and compositions for detecting HER2 gene status.
摘要:
The present invention relates to chromogenic (calorimetric) in situ hybridization (CISH) and nucleic acid probes useful for in situ hybridization. Specifically, the present invention provides methods, kits, and compositions for performing bright field cancer diagnostics employing chromogenic in situ hybridization (e.g. to detect gene amplifications, gene translocations, and chromosome polysomy). In preferred embodiments, the present invention provides CISH methods, kits and compositions for detecting HER2 gene status.